Back to search results

A Study of MK-7262 and Enlicitide in Healthy Participants

This study is looking for healthy volunteers aged 19 to 55 to understand how two drugs, MK-7262 and Enlicitide, behave in the body. Specifically, researchers want to see how much of each drug is absorbed and how long it stays in your system after you take a single dose of both. To join, you should be in good general health with a body mass index (BMI) between 18 and 32. People with significant medical or mental health conditions cannot participate. The study aims to enroll 30 participants. The study's success will be measured by tracking the levels of MK-7262 and Enlicitide in your blood over about 8 days.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 30 healthy participants.
What's involved
You will receive single doses of MK-7262 and Enlicitide. Blood samples will be taken before and at various times for up to 8 days after you take the drugs.
Compensation
Not stated in the trial record.
Follow-up
Your drug levels will be measured for up to 8 days after taking the doses.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07619443

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Recruiting
PHASE1Ages 19–55InterventionalBasic science
Merck Sharp & Dohme LLC
~30 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:MK-7262Enlicitide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262
Measured over Predose and at designated time points post-dose (up to 8 days)
+3 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is in good health before randomization
Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive

Exclusion

Has a history or presence of clinically significant medical or psychiatric condition or disease
Has a history of cancer

What this trial measures

  • Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262Predose and at designated time points post-dose (up to 8 days)

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.

  • AUC0-inf of EnlicitidePredose and at designated time points post-dose (up to 8 days post-dose)

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.

  • Maximum Plasma Concentration (Cmax) of MK-7262Predose and at designated time points post-dose (up to 8 days post-dose)

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.

  • Cmax of EnlicitidePredose and at designated time points post-dose (up to 8 days post-dose)

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.